WallStreetZenWallStreetZen

NASDAQ: SYRS
Syros Pharmaceuticals Inc Stock

Open Broker Account
$3.95-0.01 (-0.25%)
Updated Dec 1, 2022
SYRS Price
$3.95
Fair Value Price
$30.83
Market Cap
$79.89M
52 Week Low
$3.52
52 Week High
$43.30
P/E
-0.24x
P/B
0.62x
P/S
2.59x
PEG
N/A
Dividend Yield
N/A
Revenue
$23.44M
Earnings
-$113.69M
Gross Margin
100%
Operating Margin
-468.08%
Profit Margin
-485.1%
Debt to Equity
1.2
Operating Cash Flow
-$115M
Beta
1.17
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

SYRS Overview

Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. It has target discovery, research collaboration, and option agreement with Incyte Corporation to identify therapeutic targets with a focus on myeloproliferative neoplasms; and a license agreement with TMRC Co. Ltd. for the development and commercialization of tamibarotene. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.

Zen Score

Industry Average (29)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how SYRS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

SYRS ($3.95) is undervalued by 87.19% relative to our estimate of its Fair Value price of $30.83 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
SYRS ($3.95) is significantly undervalued by 87.19% relative to our estimate of its Fair Value price of $30.83 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
SYRS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more SYRS due diligence checks available for Premium users.

Be the first to know about important SYRS news, forecast changes, insider trades & much more!

SYRS News

Valuation

SYRS fair value

Fair Value of SYRS stock based on Discounted Cash Flow (DCF)
Price
$3.95
Fair Value
$30.83
Undervalued by
87.19%
SYRS ($3.95) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
SYRS ($3.95) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
SYRS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

SYRS price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-0.24x
Industry
14.11x
Market
22.16x

SYRS price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
0.62x
Industry
4.98x
SYRS is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

SYRS's financial health

Profit margin

Revenue
$3.9M
Net Income
-$30.3M
Profit Margin
-777.5%
SYRS's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
SYRS's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$284.7M
Liabilities
$155.6M
Debt to equity
1.2
SYRS's short-term assets ($252.31M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
SYRS's short-term assets ($252.31M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
SYRS's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
SYRS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$35.8M
Investing
$6.2M
Financing
$142.1M
SYRS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

SYRS vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
SYRS$79.89M+1.27%-0.24x0.62x
DARE$80.58M-1.05%-2.64x3.06x
FREQ$78.99M-1.79%-0.91x0.96x
ARMP$81.33M0.00%-2.18x1.78x
CLNN$78.25M+0.94%-2.79x-8.40x

Syros Pharmaceuticals Stock FAQ

What is Syros Pharmaceuticals's quote symbol?

NASDAQ: SYRS) Syros Pharmaceuticals trades on the NASDAQ under the ticker symbol SYRS. Syros Pharmaceuticals stock quotes can also be displayed as NASDAQ: SYRS.

If you're new to stock investing, here's how to buy Syros Pharmaceuticals stock.

What is the 52 week high and low for Syros Pharmaceuticals (NASDAQ: SYRS)?

(NASDAQ: SYRS) Syros Pharmaceuticals's 52-week high was $43.30, and its 52-week low was $3.52. It is currently -90.88% from its 52-week high and 12.22% from its 52-week low.

How much is Syros Pharmaceuticals stock worth today?

(NASDAQ: SYRS) Syros Pharmaceuticals currently has 20,225,921 outstanding shares. With Syros Pharmaceuticals stock trading at $3.95 per share, the total value of Syros Pharmaceuticals stock (market capitalization) is $79.89M.

Syros Pharmaceuticals stock was originally listed at a price of $181.50 in Jun 30, 2016. If you had invested in Syros Pharmaceuticals stock at $181.50, your return over the last 6 years would have been -97.82%, for an annualized return of -47.16% (not including any dividends or dividend reinvestments).

How much is Syros Pharmaceuticals's stock price per share?

(NASDAQ: SYRS) Syros Pharmaceuticals stock price per share is $3.95 today (as of Dec 1, 2022).

What is Syros Pharmaceuticals's Market Cap?

(NASDAQ: SYRS) Syros Pharmaceuticals's market cap is $79.89M, as of Dec 3, 2022.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Syros Pharmaceuticals's market cap is calculated by multiplying SYRS's current stock price of $3.95 by SYRS's total outstanding shares of 20,225,921.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.